Brind.
Part of AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.

How could the development of ABBV-466 affect AstraZeneca's market position?

Possible What happens if… A possibility worth considering, not a forecast.

AbbVie's new immunology drug may increase pressure on AstraZeneca The development of ABBV-466, a next-generation immunology drug, could strengthen AbbVie's market standing, thereby increasing competitive pressure on AstraZeneca. ABBV-466 combines risankizumab, the active ingredient in Skyrizi, with trosunilimab. In Phase 2a studies, the drug demonstrated higher rates of remission among patients with Crohn's disease compared to Skyrizi and trosunilimab monotherapy. If these results are confirmed in Phase 3 studies, ABBV-466 could become a strong successor to Skyrizi, which currently generates significant sales for AbbVie. As AstraZeneca is already identified as a direct competitor to AbbVie in the biopharmaceutical sector, this pipeline advancement could challenge AstraZeneca's market share.

Reported by 1 independent outlet Written Friday
Effect
Mild negative
How direct
Brind's reasoning
When
Within months
The story
No new developments lately

How it reaches AstraZeneca

Reported by news outletsBrind's reasoning

Tap any step to see the evidence behind it.

The facts so far

As reported. Each one links to where it comes from.

  • Skyrizi generated almost $10 billion in sales in the first half of the year, up 27% year over year.fool.com
  • Skyrizi's web of patents may begin to expire in the U.S. by 2033.fool.com
  • ABBV-466 achieved higher rates of remission among patients with Crohn's disease than Skyrizi and trosunilimab monotherapy in Phase 2a.fool.com
  • AbbVie and AstraZeneca are direct competitors in oncology and dyslipidemia.fool.com

Why it matters

For AstraZeneca, the development of a successful successor drug by AbbVie represents a direct challenge to its market position in the biopharmaceutical space. As a direct competitor, AstraZeneca must monitor AbbVie's pipeline closely, especially in immunology, to protect its revenue streams and maintain therapeutic dominance against rivals who are actively planning for patent cliffs.

This situation is part of a broader industry trend where major pharmaceutical companies, like AbbVie, are proactively managing the lifecycle of blockbuster drugs. Skyrizi, which is AbbVie's biggest growth driver, faces potential biosimilar competition by 2033, forcing the company to launch next-gen drugs like ABBV-466 to ensure long-term financial health.

What we don't know yet

  • Will ABBV-466 successfully pass Phase 3 studies?
  • How will ABBV-466's eventual market entry specifically impact the immunology segment where AstraZeneca operates?

What would change this answer

ABBV-466 successfully completes Phase 3 studies and receives approvalThe effect on AstraZeneca would become stronger and more immediate as AbbVie gains a new, powerful market asset.
AbbVie fails to confirm ABBV-466's results in Phase 3 studiesThe competitive pressure on AstraZeneca would likely fade, leaving AbbVie to rely on other pipeline candidates.

Who else could feel it

Other possible ripples from the same event.

Reporting

Keep going

The full eventAbbVie advances next-gen drug development to replace Skyrizi Everything aboutAstraZeneca

Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.